A major public health milestone has emerged from a global cervical cancer vaccine push, with Gavi announcing that 1.4 million future deaths have been prevented through a three-year HPV immunization effort. The announcement came as the world marked World Cervical Cancer Elimination Day, underscoring the growing impact of affordable vaccines in low-income countries.
Millions of Girls Protected
Gavi revealed that 86 million girls now have protection against HPV, the leading cause of cervical cancer. The organization credited a strong partnership between governments, global health agencies, and vaccine manufacturers, which enabled widespread rollout across poorer nations. This progress highlights how coordinated action can shift the long-term outlook of women’s health.
Burden of Cervical Cancer in Low-Income Countries
Cervical cancer caused by HPV disproportionately affects women in low-income regions. Many countries still lack screening services and timely treatment options. In 2022 alone, 350,000 women died from cervical cancer, with 90 percent of those deaths occurring in resource-limited settings. The new figures show how expanded vaccination can reverse these severe inequalities.
Africa Leads in Coverage Growth
Across Africa, HPV vaccine coverage has risen sharply. Only four percent of girls had received the vaccine in 2014. By the end of 2024, the rate had reached 44 percent, surpassing Europe’s 38 percent. Health officials attribute this growth to broad community engagement, improved supply chains, and increased political will to prioritize women’s health.
Lower Costs Boost Global Access
Gavi emphasized that the cervical cancer vaccine push succeeded partly because manufacturers agreed to reduce prices for lower-income countries. The alliance used its purchasing power to secure doses costing between $2.90 and $5.18, compared to prices exceeding $100 in wealthier nations. The approach enabled about 50 poorer countries to access reliable vaccine supplies.
A Collaborative Path Toward Elimination
Gavi’s chief executive Sania Nishtar praised the commitment shown by governments and partner organizations that helped reach millions of girls. She noted that despite the progress, cervical cancer still kills one woman every two minutes. Continued vaccination remains essential to achieve global elimination goals.
Single-Dose Schedule Accelerates Progress
The World Health Organization approved a shift to a single-dose HPV vaccination schedule in 2022. This decision effectively doubled the number of girls who can be reached using existing vaccine stocks. The change is now speeding progress toward worldwide elimination of one of the most preventable cancers affecting women.
